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Abstract 
Purpose: Herpes zoster (HZ), or shingles, is a clinical syndrome resulting from the reactivation of latent varicella 
zoster virus (VZV) within the sensory ganglia. We evaluated the safety and tolerability of ES16001 (ethanol extract of 
Elaeocarpus sylvestris var. ellipticus), a novel inhibitor of varicella zoster virus reactivation in healthy adults.
Method: Single‑center, randomized, double‑blind, placebo‑controlled, single and multiple ascending dose (SAD and 
MAD, respectively) studies were conducted in 20‑ to 45‑year‑old healthy adults without chronic disease. In the SAD 
study (n = 32), subjects randomly received a single oral dose of 240, 480, 960, or 1440 mg ES16001 or a placebo. In the 
MAD study (n = 16), subjects randomly received once daily doses of 480 or 960 mg ES16001 or a placebo for 5 days. 
The safety and tolerability of the drug were evaluated by monitoring participants’ treatment emergent adverse events 
(TEAEs) and vital signs, electrocardiograms (ECGs), physical examinations, and clinical laboratory tests.
Results: In the SAD study, 11 adverse reactions were seen in 5 subjects, and in the MAD study, 8 adverse reactions 
were seen in 6 subjects. All adverse reactions were mild, and no serious adverse reactions occurred. The most com‑
mon adverse reaction was an increase in alanine aminotransferase (ALT), but all test values were in the clinically 
non‑significant range, and their clinical significance was judged to be small considering the fact that most of the test 
values returned to normal immediately after the end of drug administration.
Conclusion: ES16001 has good safety and tolerability when administered both once and repeatedly to healthy 
subjects. Further research is needed to identify any possible drug‑induced hepatotoxicity, which appears infrequently. 
Our findings provide a rationale for further clinical investigations of ES16001 for the prevention of HZ.
Trial registration: CRIS, KCT0006066. Registered 7 April 2021—Retrospectively registered, https:// cris. nih. go. kr/ cris/ 
search/ detai lSear ch. do/ 19071).
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Introduction
Varicella zoster virus (VZV) is generally a childhood 
infection and causes chickenpox. It moves along the 
entire nerve axis in the body and hides in the dorsal root 
ganglion, cranial ganglion, and autonomic ganglion, and 
can reactivate when the host’s immunity decreases, caus-
ing shingles [1]. This clinical form of shingles is charac-
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usually occurs in a restricted dermatomal distribution 
[2]. Although herpes zoster can occur at any age, it is 
mainly a disease of adults > 60  years of age. The recur-
rence rate of shingles is reported to be about 5% or more; 
it is a difficult disease to treat because existing shingles 
treatments cannot block the reactivation of the virus 
latent in the ganglion [3]. Therefore, inhibition of VZV 
reactivation is known to be an important factor in the 
treatment of shingles.
Currently, antiviral drugs for the treatment of VZV-
associated diseases include acyclovir (ACV), valacyclovir, 
famciclovir/penciclovir, and foscarnet that aim to inhibit 
viral DNA polymerase [4, 5]. While these antiviral drugs 
are effective and relatively safe, a number of adverse 
reactions are associated with their use such as head-
ache, vomiting, diarrhea, nausea, phlebitis, and abdomi-
nal pain. Furthermore, VZV strains resistant to these 
antiviral drugs have been reported, emphasizing the 
importance of developing novel therapeutic agents for 
VZV-associated diseases [6, 7]. However, no other agents 
have been developed so far, and current treatments can-
not block the reactivation of VZV, which is latent in the 
ganglion.
Elaeocarpus sylvestris var. ellipticus (ES) is a genus of 
tropical and subtropical evergreen trees and shrubs. 
Its region of distribution includes the subtropical zone 
from Jeju in Korea to southern China, Okinawa, Kyushu 
(Japan), and Taiwan [8]. ES is used as a landscape tree and 
is fast-growing and easy to breed with strong adaptability 
[9]. A recent study reported that a 70% ethanol extract 
of ES inhibits the replication of human cytomegalovi-
rus (HCMV), which causes megacytosis, in  vitro [10]. 
In addition to its anti-HCMV effect, the ethanol extract 
of ES has been reported to possess antioxidant activity 
and protect mice from gamma-ray-induced immuno-
suppression [11, 12]. In our previous study, a 50% etha-
nol extract (ESE) of ES inhibited the expression of VZV 
replication-related genes and cell death due to viral infec-
tion. It also has an inhibitory effect on peripheral and 
central inflammatory pain that can be caused by herpes 
[13]. In addition, we confirmed the effect of ESE on the 
activity of VZV through hollow fiber assay using VZV-
infected Vero cells. Further, cells and viruses obtained 
in the hollow fiber assay were treated in cultured Vero 
cells to confirm the effect of ESE on VZV reactivation. 
For the quantification of VZV, viral DNA was extracted 
and qRT-PCR was used to measure the expression level 
of the ORF38 gene, which is involved in the viral replica-
tion process. We determined that the activity of VZV was 
greatly suppressed in the ESE-treated group. Particularly, 
in the group administered 50 mg/kg and 100 mg/kg ESE, 
the reactivation rates were − 4.2% and − 60.4%, respec-
tively, indicating that ESE inhibited the reactivation of 
VZV (Additional file 1: Table S1). These data suggest that 
ES16001 might be clinically more effective than existing 
treatments, providing a rationale for the clinical develop-
ment of this drug. Therefore, in this clinical trial, we eval-
uated the safety and tolerability of ES16001 administered 
by single or repeated oral administration to healthy adult 
subjects.
Materials and methods
This clinical trial (GNC_PT1_2018001) was reviewed 
and approved by the Institutional Review Board of Seoul 
National University Bundang Hospital (B-1908/559-002) 
and was performed in accordance with Korean Good 
Clinical Practice (KGCP). This clinical study is regis-
tered in the Clinical Research Information Service of the 
Republic of Korea (CRIS No. KCT0006066). This study is 
based on the Fortaleza’s Declaration of Helsinki in 2013 
and was conducted with the rights and welfare of the 
subjects in mind. Prior to screening, all subjects provided 
written informed consent to participate in the study after 
having been informed about the nature and purpose of 
the study and participation/withdrawal conditions.
Study drug
ES16001 is a tablet consisting of 50% ethanol extract of 
ES, one tablet of ES16001 40 mg contains 40 mg of 50% 
ethanol extract of ES out of a total of 429 mg. One tab-
let of ES16001 80  mg and 120  mg contains 80  mg and 
120  mg of ES 50% ethanol extract, respectively, out of 
a total of 429  mg. The ES16001 for oral administra-
tion and placebo tablets was supplied by Genencell Co., 
Ltd. (Yongin, Gyeonggi-do, Korea). Placebo tablets were 
identical to the ES16001 tablets (a green, rectangular, 
film-coated tablet) in size, texture, and color. The manu-
facturing process was in accordance with the good manu-
facturing process (GMP) standards, and the drugs were 
delivered and stored according to the manufacturer’s 
instructions.
Study population
This study included healthy adults 20 to 45  years old 
without chronic disease, weighing 55  kg or more, and 
weighing within ± 20% of ideal body weight (IBW):
After a total of 87 subjects agreed in writing, screen-
ing tests including demographic information verification, 
vital signs and physical examination, clinical laboratory 
tests, serum tests, urine tests, ECG, pregnancy tests, and 
concomitant drug identification were conducted on sub-
jects who agreed.
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In the SAD study, 33 subjects passed the inclusion 
and exclusion criteria, and 8 subjects (ES16001—6 sub-
jects, placebo—2 subjects) were randomly assigned to 
each dose group. One subject withdrew consent before 
drug administration due to personal reasons. Finally, 32 
subjects (24 subjects in the ES16001 group, 8 subjects in 
the placebo group) completed the clinical trial and were 
included in the safety/tolerability evaluation. In the MAD 
study, 18 subjects passed the inclusion/exclusion criteria, 
and 8 subjects (ES16001 6 subjects, placebo 2 subjects) 
were randomly assigned to each dose group. Two sub-
jects withdrew consent before drug administration due to 
personal reasons. Finally, 16 subjects (12 subjects in the 
study group, 4 subjects in the placebo group) completed 
all clinical trials (Fig. 1) and were included in the safety/
tolerability evaluation. All subjects ended the study 
according to the clinical trial protocol, and none of the 
subjects had any significant protocol violations.
Study design
This clinical trial consisted of a single-center, randomized, 
double-blind, placebo-controlled, single and multiple 
ascending dose trial. In the SAD study, four dose groups 
(240, 480, 960, and 1440 mg/day) were administered once 
to confirm safety, and in the MAD study, two dose groups 
(480 and 960  mg/day) were repeatedly administered for 
5 days to confirm safety. The dose was increased sequen-
tially from the low-dose group, and after analyzing the 
safety and tolerability results in the first-stage SAD study, 
the second-stage MAD study was begun. In the case of 
the SAD study, safety data (clinical laboratory tests, vital 
signs, ECG tests, adverse reactions, etc.) were reviewed 
for all subjects in each dose group from immediately after 
administration to 8 days after administration. In the case 
of the MAD study, safety data from immediately after 
dosing to 12 days after initial administration for all sub-
jects in each dose group were reviewed. If the data indi-
cated that a dose was safe, the next higher incremental 
dose was studied in the subsequent cohort. In the SAD 
study, cohort 1 participants received ES16001 240 mg or 
placebo, cohort 2 participants received ES16001 480 mg 
or placebo, cohort 3 participants received ES16001 
960  mg or placebo, and cohort 4 participants received 
ES16001 1,440  mg or placebo; the ES16001 or placebo 
was administered orally once. In the MAD study, cohort 
5 participants received ES16001 480  mg/day or placebo 
and cohort 6 participants received ES16001 960 mg/day 
or placebo daily for 5 days (Fig. 2).
Safety evaluation
The safety assessment included all subjects who received 
one or more doses of the clinical trial drug. Analysis was 
performed according to the administration group and 
treatment group of the clinical trial drug, and all adverse 
reactions occurred during the clinical trial were recorded. 
All adverse reactions were standardized in System Organ 
Class (SOC) and Preferred Term (PT) based on the 
Medical Dictionary for Regulatory Activities (MedDRA, 
version 23.0). The frequency (N), percentage (%) and 
number of adverse reactions (F) and adverse drug reac-
tions that occurred in this study are presented based on 
SOC and PT according to the dose group, the treatment 
group, and severity of the reaction. If there were signifi-
cant changes in the clinical laboratory test (hematology 
test, blood chemistry test, blood coagulation test, urine 
test) values, vital signs test values (systolic blood pres-
sure, diastolic blood pressure, heart rate, body tempera-
ture), and 12-lead ECG test values (ventricular rate, PR 
interval, QRS duration, QT interval, QTc interval) of any 
subject, they were described by the dose group. If each 
outcome was a clinically significant change, it was deter-
mined whether it was related to the clinical trial drug.
Statistical analysis
Statistical analyses were performed on all subjects who 
received one or more administration of the clinical trial 
drug. Continuous results are presented for each rand-
omized dose group using descriptive statistics (number 
of subjects, average, standard deviation, coefficient of 
variation, minimum, median, and maximum) for analy-
sis, and categorical results are presented by frequency 
and percentage. The values measured at the closest time 
prior to the administration time were used as baseline 
data. Outliers of the data were excluded and further ana-
lyzed at the decision of the examiner. Statistical analyses 




In the SAD study, a total of 33 subjects of 61 volun-
teers who received the screening test were enrolled in Fig. 1 Trial flowchart
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the clinical trial. In the MAD study, a total of 18 sub-
jects of 26 volunteers who received the screening test 
were enrolled in the clinical trial. Subsequently, 6 sub-
jects were randomly assigned to the treatment group 
of each administration group, and 2 subjects were ran-
domly assigned to the placebo group. All subjects were 
male. In the SAD study, the demographic characteristics 
of the subjects were age 26.42 ± 3.92  years old, height 
Fig. 2 Study outline
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174.13 ± 5.08  cm, weight 71.28 ± 8.04  kg, body mass 
index (BMI) 23.45 ± 1.89 kg/m2, and IBW 66.72 ± 4.57 kg 
(Table  1). In the MAD study, demographic character-
istics of the subjects were age 26.89 ± 6.70  years old, 
height 175.01 ± 4.99  cm, weight 71.78 ± 7.76  kg, BMI 
23.41 ± 2.05  kg/m2, and IBW 67.52 ± 4.48  kg (Table  2). 
There were no statistically significant differences in the 
demographic characteristics of subjects assigned to each 
dose group and placebo group, excluding smoking his-
tory (p-value: 0.0234, Fisher’s exact test) (Table 2).
Safety and tolerability
In the SAD study, a total of 11 adverse reactions (240 mg: 
4 cases/1 subject, 480  mg: 1 case/1 subject, 960  mg: 2 
cases/1 subject, 1440  mg: 2 cases/1 subject, placebo: 1 
cases/1 subject) in 5 of 32 subjects received at least one 
clinical trial drug or placebo. All adverse reactions were 
mild, and ADRs from the SAD study are summarized in 
Table 3. The ADR for which the causality with the clini-
cal trial drug was evaluated as ‘probably related’ was 1 
case/1 subject (alanine aminotransferase increased) in 
the 240 mg dose group and 2 cases/1 subject (aspartate 
aminotransferase increased, alanine aminotransferase 
increased) in the 1440  mg dose group. The ADR evalu-
ated as ‘possibly related’ was 1 case/1 subject (abdomi-
nal discomfort) in the 480  mg dose group. Finally, the 
number of ADRs evaluated as ‘probably not related’ was 
7 cases/4 subjects in all dose groups. There was no sig-
nificant difference (p-value = 1.0000, Fisher’s exact test) 
between the dose groups in the proportion of subjects 
Table 1 Demographic characteristics of intention‑to‑treat population: SAD study
N number of subject
p‑values by Kruskal–Wallis test (age, height, weight, BMI, and IBW)
p‑values by Fisher’s exact test (alcohol, smoking)
BMI (kg/m2) = weight (kg)/{height (m)}2
Data presented as N (%) (alcohol, smoking)













Age (years) 26.50 ± 5.75 27.67 ± 3.98 26.83 ± 1.83 26.14 ± 3.02 25.38 ± 4.72 26.42 ± 3.92 0.7707
Height (cm) 173.40 ± 7.34 173.75 ± 4.38 172.03 ± 3.86 176.37 ± 3.90 174.56 ± 5.70 174.13 ± 5.08 0.6516
Weight (kg) 74.50 ± 10.44 72.75 ± 6.99 65.63 ± 9.08 74.56 ± 6.43 69.11 ± 5.84 71.28 ± 8.04 0.1871
BMI (kg/m2) 24.67 ± 1.87 24.05 ± 1.15 22.10 ± 2.15 23.94 ± 1.46 22.70 ± 1.95 23.46 ± 1.90 0.0777
IBW (kg) 66.05 ± 6.60 66.40 ± 3.93 64.85 ± 3.47 68.73 ± 3.51 67.10 ± 5.13 66.72 ± 4.57 0.6516
Alcohol (n, %) 3 (50.0) 4 (66.7) 1 (16.7) 3 (42.9) 6 (75.0) 17 (51.5) 0.2748
Smoking (n, %) 4 (66.7) 3 (50.0) 3 (50.0) 3 (42.9) 2 (25.0) 15 (45.5) 0.6525
Table 2 Demographic characteristics of intention‑to‑treat population: MAD study
N number of subject
p‑values by Kruskal–Wallis test (age, height, weight, BMI, and IBW)
p‑values by Fisher’s exact test (alcohol, smoking)
BMI (kg/m2) = weight (kg)/{height (m)}2
Data presented as N (%) (alcohol, smoking)









Age (years) 28.43 ± 6.24 23.00 ± 1.29 31.00 ± 10.49 26.89 ± 6.70 0.0968
Height (cm) 176.80 ± 5.15 175.01 ± 3.46 171.88 ± 6.62 175.01 ± 4.99 0.2509
Weight (kg) 72.96 ± 9.36 70.99 ± 5.42 71.10 ± 10.09 71.78 ± 7.76 0.6339
BMI (kg/m2) 23.30 ± 2.54 23.19 ± 1.83 23.98 ± 1.93 23.41 ± 2.05 0.8855
IBW (kg) 69.13 ± 4.63 67.53 ± 3.10 64.70 ± 5.94 67.52 ± 4.48 0.2509
Alcohol (n, %) 5 (71.4) 2 (28.6) 4 (100) 11 (61.1) 0.0608
Smoking (n, %) 6 (85.7) 1 (14.3) 1 (25.0) 8 (44.4) 0.0235
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with more than one adverse reaction judged to have 
a causality with the clinical trial drug. The most com-
mon ADR was an increase in alanine aminotransferase, 
which occurred in 2 cases/2 subjects. Increases in AST 
and ALT (AST range: 36–108, ALT range: 58–210) were 
observed in 1 subject in the 1440 mg dose group; symp-
toms occurred on Day 14 and were followed up to Day 
35. Because symptoms persisted, on Day 42, a gastroen-
terology examination was conducted. Ursodeoxycholic 
acid and silymarin were prescribed, and the AST/ALT 
levels recovered to the normal range after six follow-up 
visits by the gastroenterologist over 144  days. This case 
was suspected drug-induced liver injury (DILI) because 
other abnormal causes cannot be found in the medical 
examination findings. There were no abnormal findings 
or changes with clinical significance as a result of clinical 
laboratory examination, vital signs, physical examination, 
or ECG.
In the MAD study, a total of 8 adverse reactions 
(480  mg: 6 cases/5 subject, 960  mg: 2 cases/1 subject) 
occurred in 6 of 16 subjects who received more than one 
dose of the clinical trial drug. All adverse reactions were 
TEAEs that occurred after administration of the clini-
cal trial drug, and all adverse reactions were classified 
as ADR because the causality with the clinical trial drug 
could not be excluded. All adverse reactions were mild, 
and ADRs from the MAD study are summarized in 
Table 4.
There were 2 cases/1 subject for which the causal-
ity of the ADRs with (diarrhea, abdominal pain) the 
clinical trial drug was evaluated as ‘probably related’ 
in the 960  mg dose group. In 6 cases/5 subjects, the 
ADRs were evaluated as ‘probably not related’ (blood 
triglycerides increased 1 case, blood creatinine phos-
phokinase increased 3 cases, hyperhidrosis 1 case, pru-
ritus 1 case) in all dose groups. No ADR occurred in 
the MAD placebo group. There was a significant dif-
ference (p-value = 0.0235, Fisher’s exact test) between 
dose groups in the proportion of subjects who had one 
or more adverse reactions (ADR evaluated as ‘prob-
ably not related’ or higher) judged to have a causal-
ity with the clinical trial drug. The most common ADR 
was an increase in blood creatinine phosphokinase, for 
which 3 cases occurred in 3 subjects. One of the sub-
jects with increased blood creatinine phosphokinase also 
had an increase in their baseline CPK level to 360 IU/L, 
higher than the normal level, and all other subjects with 
increased blood creatinine phosphokinase had their CPK 
Table 3 Summary of ADRs by treatment, SOC, and PT: SAD study
Dictionary: MedDRA 23.0
SOC: System Organ Class and PT: Preferred Term
Subject is counted once at the maximum intensity if the subject reported one or more events
Percentages are based on the subjects within each treatment

















Subjects with AEs 1 (16.7) [4] 1 (16.7) [1] 1 (16.7) [2] 1 (16.7) [3] 1 (12.5) [1] 5 (15.6) [11]
Fever 1 (16.7) [1] 1 (3.1) [1]
 Fever 1 (16.7) [1] 1 (3.1) [1]
Nervous system disorders 1 (12.5) [1] 1 (3.1) [1]
 Headache 1 (12.5) [1] 1 (3.1) [1]
General disorders and administration site conditions 1 (16.7) [2] 1 (3.1) [2]
 Pyrexia 1 (16.7) [1] 1 (3.1) [1]
 Chills 1 (16.7) [1] 1 (3.1) [1]
Investigations 2 (6.3) [4]
 c‑Reactive protein increased 1 (16.7) [2] 1 (16.7) [2] 1 (3.1) [1]
 Aspartate aminotransferase increased 1 (16.7) [1] 1 (16.7) [1] 1 (3.1) [1]
 Alanine aminotransferase increased 1 (16.7) [1] 1 (16.7) [1] 2 (6.3) [2]
Gastrointestinal disorders 1 (16.7) [1] 2 (6.3) [2]
 Diarrhea 1 (16.7) [1] 1 (16.7) [1] 1 (3.1) [1]
 Abdominal discomfort 1 (16.7) [1] 1 (3.1) [1]
Upper respiratory infection 1 (16.7) [1] 1 (3.1) [1]
 Upper respiratory infection 1 (16.7) [1] 1 (3.1) [1]
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levels reached their maximum on Day 7. But there was no 
statistically significant difference compared to pre-dose 
CPK levels.
Descriptive statistical analyses of AST and ALT lev-
els determined that these compounds had a tendency 
to decrease in most of the administration groups after 
reaching the maximum on Day 7. Statistical analysis 
of liver function tests showed a statistically significant 
increase in ALT in the 480  mg administration group. 
However, all test values were in the clinically insignificant 
range, and clinical significance was judged to be small 
based on the fact that most of them returned to normal 
values immediately after the end of the administration. 
There were no abnormal findings or changes with clinical 
significance as a result of clinical laboratory examination, 
vital signs, physical examination, or ECG.
Taken together, these results demonstrate that in 
healthy volunteers ES16001 has good safety and tolerabil-
ity in the range of doses from 240 mg to 1440 mg for a 
single dose, as well as for 480 mg to 960 mg once a day 
with repeated administration for 5 days.
Discussion
In this study, we confirmed the safety and tolerability of 
a single oral administration of ES16001 at concentrations 
of 240 to 1440 mg/kg and repeated oral administrations 
of 480 mg and 960 mg ES16001.
Since ES16001 has not been administered to humans, 
the starting dose was determined using the method for 
calculating the maximum recommended starting dose 
(MRSD) from the US FDA guideline “Estimating the 
Maximum Safe Starting Dose in Initial Clinical Trials for 
Therapeutics in Adult Healthy Volunteers”. The first step 
in estimating the MRSD proposed by the FDA guide-
lines is to convert the no observed adverse event level 
(NOAEL) calculated in the most appropriate or most 
sensitive animal species to the human equivalent dose 
(HED) taking into account the body surface area [14]. 
The doses used in the study were set based on the non-
toxic doses identified in rats and beagles [13]. Repeated 
dose toxicity tests of the 50% ethanol extract of ES were 
performed over 13  weeks in rats and beagles, and the 
NOAELs were 1000 mg/kg and 500 mg/kg, respectively. 
After converting this to the HED, the maximum recom-
mended starting doses (MRSD) calculated by applying 
the average adult weight (60  kg) and the safety factor 
(= 10) were 960 mg/day and 1620 mg/day from rats and 
beagles, respectively [13]. In addition, the pharmaco-
logically active dose (PAD) in rats was 25 mg/kg, and the 
maximum was 100 mg/kg [13]. Considering the average 
weight of human adults (60 kg), the maximum PAD was 
480  mg/day. Therefore, based on these results, 240  mg/
day was determined as the starting dose.
To characterize ESE, quantitative analysis of geraniin, 
a major component of ESE, was performed via HPLC 
analysis with gradient elution. The content of geraniin 
in the 50% aqueous EtOH extracts was determined to 
be 152.68 μg/mg (Additional file 1: Figure S1). Although 
human pharmacokinetic (PK) analysis of ESE was not 
performed in this study, PK analysis based on the geraniin 
concentration in serum of rats administered orally with 
1  g/kg of ESE calculated the  Cmax and  Tmax of geraniin 
Table 4 Summary of ADRs by treatment, SOC, and PT: MAD study
Dictionary: MedDRA 23.0
SOC: System Organ Class and PT: Preferred Term
Subject is counted once at the maximum intensity if the subject reported one or more events
Percentages are based on the subjects within each treatment











Subjects with AEs 5 (83.3) [6] 1 (16.7) [2] 6 (37.5) [8]
Investigations 4 (66.7) [4] 4 (25.0) [4]
 Blood triglycerides increased 1 (16.7) [1] 1 (6.3) [1]
 Blood creatine phosphokinase increased 3 (50.0) [3] 3 (18.8) [3]
Gastrointestinal disorders 1 (16.7) [2] 1 (6.3) [2]
 Diarrhea 1 (16.7) [1] 1 (6.3) [1]
 Abdominal pain 1 (16.7) [1] 1 (6.3) [1]
Skin and subcutaneous tissue disorder 1 (16.7) [2] 1 (6.3) [2]
 Hyperhidrosis 1 (16.7) [1] 1 (6.3) [1]
 Pruritus 1 (16.7) [1] 1 (6.3) [1]
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in the serum at 0.013 mg/mL and 2 h, respectively. Also, 
the terminal elimination half-life  (t1/2) of ESE was calcu-
lated as 7.43 h (Additional file 1: Figure S2). Human PK 
analysis will be performed together in a follow-up study 
to confirm efficacy in patients with herpes zoster.
In each dose group, subjects were randomized so that 
6 subjects received oral ES16001 and 2 received oral pla-
cebo. The results of randomization were not disclosed to 
researchers or subjects through double blinding, and pro-
gression to the high-dose group was carried out step-by-
step based on the safety and tolerability evaluation results 
of the previous dose group. During the clinical trial 
period, ALT elevation was observed as the most common 
ADR evaluated as ‘probably related’ or higher, and statis-
tically significant AST and ALT elevations were observed 
as cohort 2 (480 mg single dose group) progressed. This 
was consistent with the characteristics of the investiga-
tional drug (AST, ALT elevation findings) observed in 
preclinical studies (beagle dogs, 500 mg/kg or 1000 mg/
kg repeated administration for 4 weeks). Statistical analy-
sis of liver function tests in all dose groups determined 
that the AST and ALT values according to time and dose 
showed a statistically significant upward trend. However, 
most of the test values are within the clinically insignifi-
cant range, and in most cases, it was judged to have lit-
tle clinical significance on the basis of recovery to normal 
values immediately after the end of administration. The 
safety and tolerability of ES16001 was judged to be good 
because no abnormal findings or changes with clinical 
significance were observed in the results of other clini-
cal laboratory tests, vital signs, physical examination, and 
electrocardiogram results.
Conclusion
In conclusion, ES16001 was judged to have good safety 
and tolerability within the range of 240–1440 mg single 
dose and 5 repeated doses of 480  mg and 960  mg. Fur-
ther research is needed to understand the possibility of 
drug-induced liver injury, which appeared infrequently. 
Our findings provide a rationale for further clinical inves-
tigations of ES16001. Based on the results of this study, 
follow-up studies are also needed to confirm the safety 
and efficacy in patients with herpes zoster.
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